UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March, 2024
Commission file number: 001-37891
AC IMMUNE SA
(Exact Name of Registrant as Specified in Its Charter)
EPFL Innovation Park Building B 1015 Lausanne, Switzerland | ||
(Address of Principal Executive Offices) |
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AC IMMUNE SA | |||
By: | /s/ Andrea Pfeifer | ||
Name: | Andrea Pfeifer | ||
Title: | Chief Executive Officer | ||
By: | /s/ Christopher Roberts | ||
Name: | Christopher Roberts | ||
Title: | Chief Financial Officer |
Date: March 14, 2024
EXHIBIT INDEX
Exhibit | Description |
99.1 | Press Release dated March 14, 2024 |
99.2 | 2023 Annual Report |